Investment Rating - The report indicates a positive outlook for Adidas, with expectations of high single-digit revenue growth for FY2026 at constant exchange rates, translating to an absolute increase of approximately €2 billion [6][12]. Core Insights - Adidas achieved a revenue of €24.81 billion for FY2025, reflecting a 10% year-on-year growth at constant exchange rates, or 13% excluding the discontinued Yeezy business. Q4 revenue was €6.08 billion, up 1.8% year-on-year [2][9]. - The gross margin for FY2025 improved by 0.8 percentage points to 51.6%, with Q4 gross margin at 50.8%, an increase of 1 percentage point year-on-year [2][9]. - Operating profit for FY2025 rose by 54% to €2.056 billion, while Q4 operating profit surged by 188% to €164 million [2][9]. - The company plans to increase its dividend by 40% to €2.80 per share, with total cash returns potentially reaching up to €1.5 billion [2][9]. Summary by Sections Financial Performance - FY2025 net profit grew by 66.6% to €1.39 billion, with Q4 net profit at €91 million. Basic earnings per share increased by 76% year-on-year [2][9]. - The effective tax rate for FY2025 decreased from 26.5% to 24.3%, while Q4's effective tax rate was 12.1%, up 5.3 percentage points year-on-year [2][9]. Market and Regional Performance - All markets and channels achieved double-digit growth for FY2025, with North America showing a 4% increase for the full year, which the company considers below expectations [3][10]. - Greater China saw a 9% increase in FY2025, while Latin America experienced a 21% growth [3][10]. Product Categories - Footwear grew by 12%, accounting for 58% of sales, while apparel rose by 15%, representing 35% of sales. Football, a key category, grew by 12% and reclaimed global market leadership [4][11]. - The running category is set to launch new technology, Hyperboost, which is 40% lighter than the previous Boost technology [4][11]. Future Outlook - For FY2026, Adidas expects revenue growth in the high single digits, with operating profit projected to rise to around €2.3 billion despite challenges from US tariffs and currency fluctuations [6][12]. - The company is well-positioned to continue gaining market share in a high-quality industry, with expectations of mid-teens compound annual growth in operating profit from 2026 to 2028 [6][12].

Investment Rating - The report assigns an "Outperform" rating to several companies including Eaton, Array Technologies, Bloom Energy, and First Solar, while maintaining a "Neutral" rating for Enphase Energy and Plag Energy [1]. Core Insights - The report highlights a surge in orders for electrical equipment manufacturers in Q4 2025, driven by the upcoming launch of several GW-level data centers in 2026-2027, which the current U.S. power grid cannot support in the short term [2][3]. - It emphasizes the need for significant upgrades to the U.S. power infrastructure, including the construction of new high-voltage AC transmission lines to address inter-regional power dispatch issues, which is essential for adapting to the new economy [2]. - The report anticipates a deep collaboration between U.S. tech companies and utility companies to address power supply challenges, as both sectors increase their capital expenditure plans for the next 4-5 years [2][3]. Summary by Sections Orders and Revenue Visibility - In Q4 2025, GE Vernova reported a significant increase in gas turbine orders, with a total of 30GW, up from 20GW in 2024. The Power division's equipment order value rose from $8 billion to $18 billion, with a notable increase in demand related to data centers [6][8]. - Siemens Energy also experienced a surge in gas turbine orders, reaching 102 units in Q1 2026, with a total order value of €8.7 billion, indicating strong demand from data centers [10][12]. Infrastructure and Capital Expenditure - The report notes that U.S. utility companies are increasing their capital expenditure plans significantly, with Duke Energy leading at $103 billion, followed by NextEra Energy with $90-100 billion, reflecting a strong focus on data center load growth and infrastructure upgrades [26][28]. - The anticipated increase in electricity demand driven by AI data centers and electrification is expected to challenge the existing power infrastructure, necessitating substantial investment in upgrades and new projects [24][26]. Market Dynamics and Opportunities - The report identifies potential investment opportunities in the gas turbine supply chain, recommending companies like GE Vernova, Siemens Energy, and Mitsubishi Heavy Industries due to their strong market positions and expected growth in demand [3]. - It also highlights the importance of high-voltage transmission line upgrades, which are projected to drive demand for high-voltage equipment, suggesting a focus on companies like Hitachi and Hyundai Electric [3][20].

Investment Rating - The report assigns a rating of "Outperform" for On Holdings AG, indicating an expected total return over the next 12-18 months that exceeds the relevant market benchmark [19]. Core Insights - For FY2025, On Holdings AG achieved record high revenue and gross margin, with net sales surpassing CHF 3 billion for the first time, reflecting a 30% year-on-year increase in reported currency and a 35.6% increase in fixed currency [2][8]. - The company raised its full-year guidance for 2026, projecting at least a 23% increase in net sales at fixed currency, with a compound annual growth rate of at least 30.5% from 2023 to 2026 [5][11]. - The DTC (Direct-to-Consumer) channel's share rose to 41.8%, up 110 basis points year-on-year, indicating strong growth across various regions, particularly in APAC [2][8]. Summary by Sections Financial Performance - In FY2025, net profit was CHF 203 million, down 15.9% year-on-year, while gross margin reached 62.8% and adjusted EBITDA margin hit a record high of 18.8% [2][8]. - For Q4 FY2025, net sales reached CHF 743.8 million, a 22.6% increase year-on-year, with a gross margin of 63.9%, up 180 basis points from the previous year [3][9]. Regional Performance - The Americas, EMEA (Europe, Middle East, and Africa), and APAC regions all showed robust expansion, with APAC being the standout performer, achieving a 70.8% increase in net sales in reported currency [4][10]. - By region, net sales in the Americas totaled CHF 434.3 million, up 12.8% in reported currency, while EMEA reached CHF 183 million, up 24.2% [10]. Product Categories - Multi-category expansion significantly contributed to performance growth, with apparel sales increasing by 75.5% and accessories by 135.1% on a fixed currency basis [2][8]. - Footwear net sales reached CHF 687.3 million, reflecting a 20.8% increase in reported currency, driven by high-performance running shoes and popular product lines [10].

Investment Rating - The investment rating for the essential consumer sector in China is "Outperform" for multiple companies including Kweichow Moutai, Wuliangye, and Yili Industrial Group [1]. Core Insights - The report highlights that among the eight key tracked essential consumer industries in February 2026, five maintained positive growth, while two recorded negative growth and one remained flat. The growing industries included frozen food, condiments, beer, catering, and soft drinks, while the declining industries included sub-high-end and above liquor and dairy products. The improvement in data is attributed to the increased number of Spring Festival holidays and heightened consumer enthusiasm for travel, which boosted demand for catering and supply chain products [3][35]. Demand Summary - In February 2026, five out of eight essential consumer industries showed positive growth, with frozen food, condiments, beer, catering, and soft drinks experiencing growth. Conversely, sub-high-end and above liquor and dairy products saw declines. The overall growth rate improved for seven industries compared to the previous month, primarily due to the Spring Festival holidays and increased consumer travel [3][35]. Price Summary - The report indicates that in February, the wholesale price of high-end liquor rebounded month-on-month, while sub-high-end and below liquor prices mostly fell. Discounts on liquid milk and condiments decreased, with average discount rates for liquid milk increasing by 4.7 percentage points and condiments by 1.2 percentage points compared to January. Convenience food discounts increased, while discounts for beer, soft drinks, and infant formula remained stable [4][36]. Cost Summary - In February, the spot cost indices for six categories of consumer goods generally fell, while futures cost indices mostly rose. The spot cost indices for soft drinks, instant noodles, frozen food, beer, condiments, and dairy products changed by -1.28%, -1.03%, -0.52%, -0.52%, +0.06%, and +0.27% respectively. Year-on-year changes for can, plastic, paper, and glass prices were +12.1%, -0.3%, -7.4%, and -17.7% respectively [4][37]. Capital Flow Summary - As of the end of February, the net inflow of Southbound Stock Connect funds was 80.32 billion yuan, an increase from 61.73 billion yuan in the previous month. The essential consumer sector's market value accounted for 5.86%, up by 0.04 percentage points from the previous month. The dairy industry represented 17.2% of the Southbound Stock Connect market value, while the food additive industry accounted for 14.4% [5][38]. Valuation Summary - At the end of February, the PE historical quantile for A-share food and beverage was 17% (20.5x), remaining stable from the previous month. The sub-sectors with lower quantiles included beer (1%, 20.6x) and liquor (12%, 18.3x). The median valuation for A-share food and beverage leaders was 22x, unchanged from the previous month [5][39]. Recommendations - The report suggests several favorable aspects for allocating essential consumption stocks, including increased international capital inflow into China, low institutional allocation levels, and the expectation of rising dividend rates. It recommends focusing on companies that align with fundamental and dividend yield improvement logic, such as Mengniu Dairy, Yili Industrial Group, and Tsingtao Brewery, as well as those favored by long-term institutional investors like Luzhou Laojiao and Kweichow Moutai [6][40].

Market Performance - Southeast Asia ETF rose by 1.24% during the period from February 14 to February 27, 2026, outperforming the US and India but underperforming Africa, Japan, the UK, Latin America, and China[3] - Thailand's iShares MSCI ETF surged by 6.76%, outperforming by 5.51 percentage points, driven by strong export growth and interest rate cuts[4] - Indonesia's iShares MSCI ETF gained 0.28%, underperforming by 0.96 percentage points, supported by economic growth and a trade agreement with the US[4] - Singapore's iShares MSCI ETF rose by 1.05%, underperforming by 0.19 percentage points, with initial gains followed by a mild consolidation due to moderating inflation[4] Country-Specific Insights - Malaysia's iShares MSCI ETF fell by 1.68%, underperforming by 2.92 percentage points, despite record-high trade data and a structural breakthrough in services trade[4] - Vietnam's Global X MSCI ETF advanced by 1.87%, outperforming by 0.63 percentage points, buoyed by record foreign inflows and optimistic long-term assessments[4] Trading Volume and Liquidity - Global X FTSE Southeast Asia ETF's trading volume decreased by 52.1% to 341,000 shares, indicating a significant drop in liquidity[14] - iShares MSCI Singapore ETF's trading volume fell by 38.8% to 5.948 million shares, reflecting a similar trend across the region[15] Economic Indicators - Thailand's January export growth reached 24.4%, the fastest since 2021, significantly boosting market sentiment[23] - Indonesia's GDP growth for 2025 is projected at 5.11%, up from 5.03% in 2024, indicating a steady economic recovery[17]

Liquidity Data - Year-to-date, global asset performance has become increasingly polarized, with Korea, Brazil, Taiwan, and Japan leading, while the Hang Seng Tech Index, India, and Nasdaq lagging[2] - The U.S. 10-year Treasury yield has dropped sharply by 13.6 basis points to 3.95% due to rising risk aversion[2] - In Hong Kong, short-selling turnover remains high at 20%, while southbound capital inflows have slowed to RMB 67 billion, with a turnover share of 19%[2][22] Selected Research Highlights - The "Spring Festival effect" is observed in both Hong Kong and A-shares, with a tendency for a rebound post-holiday[67] - Hong Kong IPO fundraising is expected to reach HKD 644.4 billion in 2025, significantly higher than HKD 192.2 billion in 2024, indicating improved market conditions[42] - Geopolitical conflicts are impacting oil prices and shipping, with potential implications for market stability[50] Market Trends - U.S. equities are showing extreme internal dispersion, with repricing reaching a near-term peak[67] - Recent U.S. inflation expectations have weakened, reducing their linkage to oil, copper, and the U.S. dollar index[67] - The People's Bank of China has cut the FX risk reserve ratio, which does not alter the medium- to long-term trend of the RMB[67]

Investment Rating - The report assigns a positive investment rating, indicating a "Best-in-Class" potential for the company's product DB1311/BNT324 (B7H3 ADC) in treating late-line castration-resistant prostate cancer (CRPC) [3][9]. Core Insights - The latest efficacy and safety data for DB1311/BNT324 was presented at the 2026 ASCO Genitourinary Cancers Symposium, showcasing promising results in a Phase I/II clinical trial involving 104 patients [1][6]. - The median follow-up time was 9.2 months, with significant response rates: PSA50 response rate at 35.4%, confirmed overall response rate (ORR) at 34.5%, and disease control rate (DCR) at 87.9% [2][7]. - The median radiographic progression-free survival (rPFS) was reported at 11.3 months, with 6-month and 9-month rPFS rates of 72% and 63%, respectively [2][7]. - The safety profile was consistent with previous reports, primarily consisting of Grade 1-2 adverse events [2][7]. Summary by Sections Clinical Data - The clinical trial data included 104 patients, with 68 receiving 6 mg/kg Q3W treatment and 34 receiving 9 mg/kg Q3W treatment, and 53% of the patients were White [1][6]. - Among 82 evaluable patients, the median duration of response (DOR) was 10.2 months, indicating a strong survival benefit [2][7]. Comparative Analysis - The rPFS rate of 72% compares favorably against other treatments, such as Novartis' Lu177 and Johnson & Johnson's KLK2*CD3 TCE, which reported lower rPFS rates [3][9]. - The report highlights the potential of DB1311 to outperform existing therapies in terms of survival data, suggesting a strong competitive position in the market [3][9].

Group 1 - The investment rating for Galaxy Entertainment is maintained at OUTPERFORM with a target price of HKD 47.30 [2][6][17] - The company reported a net revenue of HKD 13.83 billion for Q4 2025, representing a year-on-year increase of 22.5% and a quarter-on-quarter increase of 13.7% [3][12][13] - Adjusted EBITDA reached HKD 4.3 billion, up 32.7% year-on-year, with an adjusted EBITDA margin of 31.1%, an increase of 2.4 percentage points year-on-year [3][5][15] Group 2 - The gaming revenue increased by nearly 30% year-on-year, significantly contributing to the overall growth of the company's earnings [4][13] - The company's market share improved to 21.8% in Q4 2025, up from 20.2% in Q3 2025 and 19.8% in Q4 2024 [5][16] - The forecast for net revenue for FY 2026 and 2027 is HKD 52.48 billion and HKD 56.71 billion, respectively, with expected growth rates of 6.6% and 8.1% [6][17]

Investment Rating - The report maintains an "Outperform" rating for BeiGene [2][5][14]. Core Insights - In FY25, BeiGene achieved revenue of USD 5.34 billion, representing a 40% year-over-year increase, with product revenue of USD 5.28 billion, slightly exceeding management's guidance [3][11]. - The net profit attributable to the parent company was USD 0.29 billion, a turnaround from a loss of USD 0.64 billion in FY24, indicating a successful operational recovery [3][11]. - Management projects FY26 revenue to be between USD 6.2 billion and USD 6.4 billion, with GAAP operating profit expected to be between USD 0.7 billion and USD 0.8 billion [3][11]. Financial Summary - Revenue growth is forecasted at 55% for FY25, 40% for FY26, and 20% for FY27 [9]. - Net profit is expected to grow significantly, with projections of USD 0.61 billion for FY26 and USD 1.04 billion for FY27, reflecting a 113% and 70% increase, respectively [9][14]. - Gross profit margin is expected to remain strong at around 87.5% for FY26 and FY27 [9]. Sales Performance - Zanubrutinib generated full-year revenue of USD 3.93 billion, up 49% year-over-year, with U.S. sales contributing USD 2.8 billion [12]. - Tislelizumab achieved revenue of USD 0.74 billion, marking a 19% increase year-over-year [13]. - Collaboration product sales in China reached USD 0.62 billion, driven by growth in specific drugs [13]. Future Catalysts - Key catalysts for 1H26 include the approval of Sonrotoclax for R/R MCL and interim analysis of zanubrutinib in 1L MCL [16]. - In 2H26, significant events include the submission for accelerated approval of BTK CDAC and the initiation of a Phase 3 trial for Sonrotoclax in combination therapy for multiple myeloma [16]. Valuation - The target price is set at HKD 212.09, based on a discounted cash flow (DCF) model with a WACC of 9% and a perpetual growth rate of 4% [5][14].

Investment Rating - The report maintains an "OUTPERFORM" rating for CSPC Pharmaceutical Group with a target price of HK$13.07, while the current price is HK$10.06 [2]. Core Insights - CSPC Pharmaceutical Group has achieved multiple recognitions from multinational corporations (MNCs) and has made significant progress in innovation transformation, indicating a highly anticipated platform value [1]. - The company has completed seven external collaboration transactions, with total upfront payments reaching USD 1.71 billion and potential milestone payments exceeding USD 30 billion [10][11]. - The report highlights the company's strong research and development capabilities, particularly in cell therapy, ADC, siRNA, and mRNA technologies, which are expected to contribute to future revenue growth [3][4][5][7]. Financial Summary - Revenue projections for FY25, FY26, and FY27 are adjusted to RMB 267 billion, RMB 289 billion, and RMB 306 billion respectively, with net profit estimates revised to RMB 44 billion, RMB 46 billion, and RMB 53 billion [8]. - The company is expected to return to a growth cycle in 2026, benefiting from the commercialization of innovative oncology and metabolic products [8]. Research and Development Highlights - CSPC's small nucleic acid platform is positioned among the top tier of domestic pharmaceutical companies, with a broad pipeline targeting liver delivery for conditions such as hyperlipidemia and hypertension [4][31]. - The in vivo CAR-T product SYS6055 has received clinical approval in China, marking a significant advancement in the company's cell therapy portfolio [7][26]. - The ADC pipeline, particularly SYS6010, shows strong potential for international expansion, with ongoing clinical trials in both China and the United States [5][19][20]. Collaboration and Licensing Opportunities - The report emphasizes the potential for ongoing licensing revenue from collaborations with leading pharmaceutical companies, particularly with AstraZeneca and Madrigal [11][12]. - CSPC's partnerships are expected to generate sustainable recurring income, contributing to the company's profitability over the next 3-5 years [11][12]. Clinical Pipeline and Milestones - The report outlines several key clinical trials, including SYS6010 for non-small cell lung cancer (NSCLC) and JMT108 for melanoma, with significant data readouts anticipated in 2026 [16][22][23]. - The company is actively pursuing additional indications for its products, including breast cancer and head and neck squamous cell carcinoma [23][24].